Medline (NASDAQ:MDLN) Stock Price Expected to Rise, Citigroup Analyst Says

Medline (NASDAQ:MDLN) had its target price hoisted by investment analysts at Citigroup from $45.00 to $47.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup‘s price objective points to a potential upside of 18.21% from the company’s current price.

A number of other research firms have also recently weighed in on MDLN. TD Cowen cut their price objective on shares of Medline from $53.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Deutsche Bank Aktiengesellschaft set a $37.00 target price on Medline and gave the company a “hold” rating in a research report on Thursday, August 6th. Leerink Partners upped their target price on Medline from $43.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday. Evercore set a $39.00 price target on Medline in a research note on Thursday, August 6th. Finally, Bank of America dropped their price objective on Medline from $53.00 to $46.00 in a report on Thursday, August 6th. Twenty-three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $45.85.

Medline Price Performance

MDLN traded down $0.59 during trading on Thursday, hitting $39.76. 14,219,583 shares of the company traded hands, compared to its average volume of 7,779,503. The company has a market cap of $52.27 billion and a PE ratio of 50.33. Medline has a 1 year low of $31.37 and a 1 year high of $50.88. The company has a current ratio of 4.33, a quick ratio of 2.61 and a debt-to-equity ratio of 0.66. The stock’s 50-day simple moving average is $34.58 and its two-hundred day simple moving average is $39.53.

Medline (NASDAQ:MDLN) last posted its earnings results on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.12. The firm had revenue of $7.86 billion for the quarter. As a group, sell-side analysts anticipate that Medline will post 1.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Medline

In related news, major shareholder Private Ltd Gic sold 2,088,987 shares of the company’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total value of $73,218,994.35. Following the completion of the sale, the insider directly owned 16,453,806 shares of the company’s stock, valued at $576,705,900.30. This represents a 11.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 8,538,960 shares of company stock valued at $302,807,442 in the last ninety days. Insiders own 0.81% of the company’s stock.

Institutional Investors Weigh In On Medline

Several institutional investors have recently added to or reduced their stakes in MDLN. GAMMA Investing LLC lifted its position in Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after purchasing an additional 254 shares during the period. Whipplewood Advisors LLC purchased a new stake in Medline in the first quarter valued at $30,000. Reyes Financial Architecture Inc. purchased a new stake in Medline in the third quarter valued at $30,000. NewEdge Advisors LLC grew its position in Medline by 100.0% during the 2nd quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock worth $37,000 after purchasing an additional 475 shares during the period. Finally, Allworth Financial LP grew its position in Medline by 86.2% during the 2nd quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock worth $41,000 after purchasing an additional 487 shares during the period.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported Q3 EPS of $0.44, above the $0.32 consensus, on revenue of $7.86 billion. Coverage also points to raised full-year growth expectations and a planned $1 billion share buyback. Medline Q3 earnings and outlook Q3 beat and buyback
• Positive Sentiment: Analysts reinforced a bullish outlook: BTIG reiterated Buy with a $55 target, Leerink Partners raised its target to $46 and rated the stock Outperform, and Barclays also issued a Buy rating. BTIG rating Leerink Partners target Barclays rating
• Neutral Sentiment: Medline plans price increases in 2027 to help offset inflation. This could support margins, though the effect will depend on customer response and costs. Pricing plans and Q3 results
• Negative Sentiment: Reports say quarterly profit fell and the company reaffirmed its FY26 adjusted EBITDA outlook, tempering the upbeat earnings and growth news. Q3 profit and outlook
• Negative Sentiment: A law firm announced an investigation into potential securities-fraud claims related to product-quality issues. This is an allegation and investigation, not a finding of wrongdoing, but it could add reputational and legal uncertainty. Investigation announcement

About Medline

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.